Catalyst
Slingshot members are tracking this event:
FDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CLVS |
|
|
||||
Additional Information
“The acceptance of the rucaparib NDA submission represents an important milestone for rucaparib, and for Clovis,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “There is tremendous need for additional therapeutic options for patients with advanced mutant BRCA ovarian cancer and we look forward to cooperating with FDA on the rucaparib NDA review.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 23, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rucaparib, Advanced Mutant Brca Ovarian Cancer, Priority Review, Nda Filing
